Becton Dickinson (BDX) announced full enrollment of the iliac artery patient cohort in its AGILITY investigational device exemption study, a prospective, multi-center study evaluating the Revello vascular covered stent in patients with peripheral arterial disease.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BDX Upcoming Earnings Report: What to Expect?
- Becton Dickinson receives FDA clearance, CE mark for enteric bacterial panels
- BD’s New Vascular Access Study: What Investors Need to Know
- BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access
- Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications